Kura Oncology, Inc. Segments Disclosure
14. Segment Reporting
Our CODM manages our operations on an integrated basis for the purpose of allocating resources. When evaluating our financial performance, the CODM regularly reviews total revenues, total expenses, and research and development expenses by project and the CODM makes decisions using this information.
The table below is a summary of the segment profit or loss, including significant expenses, in thousands:
|
Years Ended December 31, |
|
|||||||||
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Revenue |
|
|
|
|
|
|
|
|
|||
Product revenue, net |
$ |
2,132 |
|
|
$ |
— |
|
|
$ |
— |
|
Collaboration revenue |
|
65,350 |
|
|
|
53,883 |
|
|
|
— |
|
Total revenue |
|
67,482 |
|
|
|
53,883 |
|
|
|
— |
|
Less: |
|
|
|
|
|
|
|
|
|||
Cost of product sales |
|
57 |
|
|
|
— |
|
|
|
— |
|
Ziftomenib-related costs |
|
142,579 |
|
|
|
79,338 |
|
|
|
35,933 |
|
Darlifarnib-related costs |
|
26,714 |
|
|
|
18,829 |
|
|
|
10,629 |
|
Tipifarnib-related costs |
|
3,490 |
|
|
|
4,770 |
|
|
|
12,190 |
|
Discovery stage program-related costs |
|
7,230 |
|
|
|
6,621 |
|
|
|
5,399 |
|
Research and development personnel costs and other expenses |
|
58,474 |
|
|
|
45,789 |
|
|
|
38,424 |
|
Share-based compensation expense |
|
37,108 |
|
|
|
33,897 |
|
|
|
28,082 |
|
Other segment expenses(1) |
|
95,461 |
|
|
|
57,834 |
|
|
|
35,147 |
|
Total operating expenses |
|
371,113 |
|
|
|
247,078 |
|
|
|
165,804 |
|
Other income (expenses) |
|
|
|
|
|
|
|
|
|||
Interest and other income, net |
|
26,774 |
|
|
|
22,849 |
|
|
|
14,722 |
|
Interest expense |
|
(1,512 |
) |
|
|
(1,619 |
) |
|
|
(1,549 |
) |
Income tax expense |
|
(297 |
) |
|
|
(2,018 |
) |
|
|
— |
|
Segment and net loss |
$ |
(278,666 |
) |
|
$ |
(173,983 |
) |
|
$ |
(152,631 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.